查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1415024

非专利药注射剂市场：按产品类型、应用、分销管道划分 - 2024-2030 年全球预测

Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年非专利药市场规模将达300亿美元，预计2024年将达331.2亿美元，2030年将达到606.6亿美元，复合年增长率为10.57%。

全球非专利药注射剂市场

主要市场统计
基准年[2023] 300亿美元
预测年份 [2024] 331.2亿美元
预测年份 [2030] 606.6亿美元
复合年增长率（%） 10.57%
仿製药注射剂市场-IMG1

非专利药注射剂是透过注射给药的非品牌药物，具有与品牌产品相同的活性成分、规格、剂型、给药途径、品质、性能特征和预期用途。它通常在原厂产品的专利到期后出售。非专利药注射剂透过提供具有成本效益的品牌药物替代品，有助于节省医疗费用并为患者提供便利。对更实惠的药物的需求不断增长，以及由于几种品牌注射剂的专利到期而导致学名药进入市场，推动了仿製药注射剂市场的发展。世界各国政府的成本控制政策也支持广泛普及具有成本效益的非专利注射剂。此外，需要注射药物治疗的慢性疾病的增加也支持了市场的成长。儘管成长前景广阔，但市场在维持高品质标准方面面临挑战，如果管理不当，可能会导致召回和声誉受损。此外，市场竞争激烈且价格下降，这可能会阻碍非专利注射剂的采用。然而，研究重点是先进的药物输送系统、生物相似药开发、永续生产以及提高产品稳定性和保质期的配方进步，为市场扩张提供了利润丰厚的机会。

区域洞察

美国尤其是美国的非专利药注射剂市场正在经历显着成长。由于学名药到期、政府努力最大限度地降低医疗成本以及慢性病的增加，该地区对负担得起的专利到期药的需求正在迅速增加。除了发达的医疗保健产业外，美洲地区也受惠于竞争激烈的市场形势，许多参与企业不断致力于推出新产品和具成本效益的製造流程。欧洲、中东和非洲（Europe, Middle East, and Africa）地区的非专利注射药物市场正在稳步成长。这一业绩是由旨在促进学名药使用和对生物相似药的重视的政府支持性卫生政策所推动的。虽然欧洲市场尤其受益于确保高品质产品的严格监管标准，但成本效益仍然是非专利注射剂普及的驱动力。随着医疗基础设施的改善和药物取得的增加，中东和非洲的市场正在稳步发展。目前非专利仿製药领域在亚太地区正在迅速扩张。印度和中国因其庞大的人口基数、不断上涨的医疗成本以及政府对学名药生产的支持政策而成为这一增长的主要贡献者。该地区还拥有大量学名药生产商，支持了当地市场的成长。此外，慢性病盛行率的不断上升以及新兴国家加强医疗保健系统的共同努力，为亚太地区非专利药注射剂市场的成长奠定了坚实的基础。

FPNV定位矩阵

FPNV 定位矩阵对于评估非专利注射剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对非专利注射剂市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-非专利注射剂市场的市场规模和预测是多少？

2-在非专利药市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-非专利药注射剂市场的技术趋势和法律规范是什么？

4-非专利药市场主要供应商的市场占有率是多少？

5-进入非专利注射药市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和对高性价比药物的需求
      • 重视延长专利有效期限及采用学名药
      • 政府对学名药和注射剂的有利核准
    • 抑制因素
      • 病人和医生对品牌药物的偏好
    • 机会
      • 有关非专利注射剂的持续研发活动
      • 建立非专利注射剂生产的长期策略伙伴关係
    • 任务
      • 对注射品质和製造差异的担忧
  • 市场区隔分析
    • 产品：易于取得和熟悉将增加各个治疗领域小分子注射剂的消费
    • 类型：在持续研究和开发具有成本效益的新治疗方法中对非专利细胞激素和单株抗体的需求
    • 应用：非专利注射剂在心臟病学和肿瘤学领域的显着优势需要长期且永续的药物成本
    • 通路：越来越青睐提供便利且价格具竞争力的网路商店
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章非专利注射剂市场：副产品

  • 介绍
  • 聚合物注射
  • 低分子注射液

第七章非专利注射剂市场：按类型

  • 介绍
  • 细胞激素
  • 胰岛素
  • 单株抗体
  • 疫苗

第八章非专利注射剂市场：依应用分类

  • 介绍
  • 心臟病学
  • 糖尿病
  • 免疫学
  • 肿瘤学

第九章非专利注射剂市场：依通路

  • 介绍
  • 医院药房
  • 网路处方笺店
  • 零售药房

第十章美洲非专利注射剂市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区非专利注射剂市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲非专利注射剂市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析
    • 新产品发布和功能增强
    • 奖项/奖励/扩展

第14章竞争产品组合

  • 主要公司简介
    • Amgen Inc.
    • AstraZeneca PLC
    • Aurobindo Pharma Limited
    • Baxter International Inc.
    • Biocon Limited
    • Biological E. Limited
    • Bristol-Myers Squibb Company
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Endo International PLC
    • Eugia US LLC
    • Fresenius Kabi AG
    • Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
    • GlaxoSmithKline PLC
    • Hikma Pharmaceuticals PLC
    • Johnson & Johnson Services, Inc.
    • Lupin Limited
    • Meitheal Pharmaceuticals, Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Samsung Biologics Co., Ltd.
    • Sanofi SA
    • Somerset Pharma, LLC
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
  • 主要产品系列

第十五章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-C002B1C9980C

[187 Pages Report] The Generic Injectables Market size was estimated at USD 30.00 billion in 2023 and expected to reach USD 33.12 billion in 2024, at a CAGR 10.57% to reach USD 60.66 billion by 2030.

Global Generic Injectables Market

KEY MARKET STATISTICS
Base Year [2023] USD 30.00 billion
Estimated Year [2024] USD 33.12 billion
Forecast Year [2030] USD 60.66 billion
CAGR (%) 10.57%
Generic Injectables Market - IMG1

Generic injectables are non-branded pharmaceuticals that are administered by injection and have the same active ingredients, strength, dosage form, route of administration, quality, performance characteristics, and intended use as their branded counterparts. They are typically marketed after the original branded product's patent protection has expired. Generic injectables offer a cost-effective alternative to brand-name drugs, thereby contributing to healthcare savings and increased accessibility for patients. The generic injectables market is fueled by the increasing demand for more affordable pharmaceuticals and the expiration of patents for multiple branded injectables, which allows generic versions to enter the market. Cost-containment policies by governments worldwide also drive the uptake of cost-effective generic injectables. In addition, the rise in the prevalence of chronic diseases that require injectable drugs for treatment supports the market growth. Despite the promising growth, the market faces challenges due to maintaining high-quality standards, which, if not adequately managed, can lead to recalls and reputational damage. Furthermore, the market is subject to intense competition and price erosion, which can hinder the adoption of generic injectables. However, research focusing on advanced drug delivery systems, biosimilar development, sustainable production, and formulation advancements to improve product stability and storage presents lucrative opportunities for market expansion.

Regional Insights

The market for generic injectables in the Americas, and particularly in the United States, has seen significant growth. The expiration of patents for branded drugs, government initiatives to minimize healthcare costs, and the rising prevalence of chronic diseases have resulted in a surging need for affordable generic alternatives in this region. The Americas region benefits from a well-developed healthcare sector and a competitive market landscape where numerous players are constantly engaged in the introduction of new products and cost-effective manufacturing processes. The Europe, Middle East, and Africa (EMEA) region has experienced steady growth in the generic injectables market. This performance is facilitated by supportive governmental health policies aimed at promoting the use of generics, as well as an emphasis on biosimilars. The European market, in particular, benefits from stringent regulatory standards that ensure high-quality products, while cost-effectiveness remains a driving factor behind the widespread adoption of generic injectables. In the Middle East and Africa, the market is steadily evolving with the improving healthcare infrastructure and increased accessibility to medication. The Asia-Pacific (APAC) region is currently witnessing rapid expansion in the generic injectables sector. India and China, with their vast population base, increasing healthcare expenditure, and supportive government policies for generic medicine production, are contributing significantly to this growth. The region also hosts a significant number of generic drug manufacturers, which bolster the local market growth. Additionally, the growing incidence of chronic conditions, coupled with a concerted effort to enhance healthcare systems in emerging economies, provides a robust platform for the growth of the generic injectables market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Generic Injectables Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Generic Injectables Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eugia US LLC, Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Generic Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Large Molecule Injectables
    • Small Molecule Injectables
  • Type
    • Cytokines
    • Insulin
    • Monoclonal Antibodies
    • Vaccines
  • Application
    • Cardiology
    • Diabetes
    • Immunology
    • Oncology
  • Distribution Channel
    • Hospital Pharmacy
    • Online Prescription Stores
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Generic Injectables Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Generic Injectables Market?

3. What are the technology trends and regulatory frameworks in the Generic Injectables Market?

4. What is the market share of the leading vendors in the Generic Injectables Market?

5. Which modes and strategic moves are suitable for entering the Generic Injectables Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Generic Injectables Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Increasing patent expirations and emphasis on adopting generic drugs
      • 5.1.1.3. Favorable government approvals for generic drugs & injectables
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic injectable drugs
      • 5.1.3.2. Strategic long-term partnerships to manufacture generic injectables
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with injectable quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • 5.2.2. Type: Demand for generic cytokines and monoclonal antibodies in ongoing R&D for cost-effective novel therapies
    • 5.2.3. Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • 5.2.4. Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Generic Injectables Market, by Product

  • 6.1. Introduction
  • 6.2. Large Molecule Injectables
  • 6.3. Small Molecule Injectables

7. Generic Injectables Market, by Type

  • 7.1. Introduction
  • 7.2. Cytokines
  • 7.3. Insulin
  • 7.4. Monoclonal Antibodies
  • 7.5. Vaccines

8. Generic Injectables Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Diabetes
  • 8.4. Immunology
  • 8.5. Oncology

9. Generic Injectables Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Prescription Stores
  • 9.4. Retail Pharmacy

10. Americas Generic Injectables Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generic Injectables Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generic Injectables Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player
    • 13.3.1. New Product Launch & Enhancement
      • 13.3.1.1. Endo Launches First Generic Version of Noxafil (posaconazole) Injection
    • 13.3.2. Award, Recognition, & Expansion
      • 13.3.2.1. Gland Pharma gets USFDA nod for generic injectable
      • 13.3.2.2. Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Amgen Inc.
    • 14.1.2. AstraZeneca PLC
    • 14.1.3. Aurobindo Pharma Limited
    • 14.1.4. Baxter International Inc.
    • 14.1.5. Biocon Limited
    • 14.1.6. Biological E. Limited
    • 14.1.7. Bristol-Myers Squibb Company
    • 14.1.8. Cipla Limited
    • 14.1.9. Dr. Reddy's Laboratories Ltd.
    • 14.1.10. Endo International PLC
    • 14.1.11. Eugia US LLC
    • 14.1.12. Fresenius Kabi AG
    • 14.1.13. Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
    • 14.1.14. GlaxoSmithKline PLC
    • 14.1.15. Hikma Pharmaceuticals PLC
    • 14.1.16. Johnson & Johnson Services, Inc.
    • 14.1.17. Lupin Limited
    • 14.1.18. Meitheal Pharmaceuticals, Inc.
    • 14.1.19. Merck & Co. Inc.
    • 14.1.20. Novartis AG
    • 14.1.21. Novo Nordisk A/S
    • 14.1.22. Pfizer Inc.
    • 14.1.23. Samsung Biologics Co., Ltd.
    • 14.1.24. Sanofi S.A.
    • 14.1.25. Somerset Pharma, LLC
    • 14.1.26. Sun Pharmaceutical Industries Ltd.
    • 14.1.27. Teva Pharmaceutical Industries Ltd.
    • 14.1.28. Viatris Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GENERIC INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC INJECTABLES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENERIC INJECTABLES MARKET DYNAMICS
  • FIGURE 7. GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 9. GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 191. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENERIC INJECTABLES MARKET LICENSE & PRICING